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 Introduction 
 In patients with abdominal malignancies, the occur-
rence of peritoneal carcinomatosis is associated with a 
significantly reduced life expectancy and quality of life. 
Survival correlates well with the extent of the disease at 
initial diagnosis: for patients with non-gynecologic ma-
lignancies, life expectancy drops from 9.8 months if only 
nodules of less than 5 mm are seen on a single spot to 
3.7 months if nodules larger than 2 cm are present  [1] . In 
addition, large tumor masses are frequently complicated 
by intestinal or urinary obstruction  [2] with a substantial 
impact on the quality of life of these patients.
 Treatment of peritoneal carcinomatosis is, in most 
cases, limited to palliative measures. Palliative chemo-
therapy has been shown to increase survival  [3], but cure 
is rarely achieved. In this respect, cytoreductive surgery 
followed  by hyperthermic intraperitoneal chemoperfu-
sion (HIPEC) has become a therapeutic option with cura-
tive intent for patients with limited disease. In addition to 
the primary peritoneal tumors pseudomyxoma peritonei 
and malignant peritoneal mesothelioma, it can be offered 
to suitable patients with limited peritoneal carcinomato-
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 Abstract 
 Background/Aims: Cytoreductive surgery and hyperther-
mic intraperitoneal chemoperfusion (HIPEC) can improve 
survival in selected patients with peritoneal carcinomatosis, 
but bear a significant risk of perioperative morbidity. The aim 
of this study was to prospectively evaluate the quality of life 
(QoL) following cytoreduction and HIPEC.  Methods: In this 
study including 40 patients (65% females) with different pri-
mary tumors, the EORTC QLQ-C30 questionnaire was ap-
plied prior to CS and HIPEC as well as 3, 9, and 18 months 
postoperatively.  Results: Global health status was not im-
paired significantly following HIPEC. Scales and symptom 
scores that deteriorated 3 months postoperatively (p < 0.05), 
that is, physical, role, and social functions as well as fatigue, 
pain, dyspnea, insomnia, and diarrhea, all returned to preop-
erative values within 9 months.  Conclusions: Following cy-
toreductive surgery and HIPEC, QoL returns to preoperative 
levels within 9 months. Selected patients that are likely to 
benefit oncologically from HIPEC should not be denied this 
option for fear of reduced postoperative QoL. 
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sis (as defined by Verwaal et al.  [4] ) due to colorectal car-
cinoma, mucinous appendix carcinoma, and, sometimes, 
gastric cancer and recurrent ovarian cancer. It has been 
shown that cytoreductive surgery followed by HIPEC im-
proves survival in selected patients with colorectal carci-
noma  [4] .
 Cytoreductive surgery aims to resect all tumor nod-
ules larger than 2.5 mm and HIPEC is used to treat any 
residual microscopic disease. The advantage of HIPEC 
lies in the high concentration of hydrophilic chemo-
therapeutic agents that can be achieved locally with low 
plasma concentrations compared to systemic applica-
tion  [5] .
 The procedure, however, bears a significant risk of 
morbidity and mortality  [6–9] . In a study of 67 patients 
by Schmidt et al., the overall morbidity amounted to 34% 
 [10] and the extent of surgery turned out to be the main 
contributing factor. Hence, the potential survival benefit 
must be weighed against a possible loss in quality of life 
associated with the procedure and its complications.
 Previous retrospective studies described an acceptable 
or good quality of life after HIPEC  [10–12] , but no pro-
spective evaluation had been published when we started 
the present study. We, therefore, aimed to prospectively 
evaluate the health-related quality of life in peritoneal 
cancer patients undergoing cytoreduction and HIPEC. 
The primary question was whether the quality of life after 
cytoreductive surgery and HIPEC would return to preop-
erative levels and if so when.
 Patients and Methods 
 Study Design and Participants 
 This study was designed as an analysis of prospectively col-
lected quality-of-life data in patients undergoing cytoreductive 
surgery and HIPEC. The quality-of-life assessment was routinely 
conducted for all patients receiving cytoreductive surgery and 
HIPEC at our department during the study period. Inclusion and 
exclusion criteria were therefore the same as for HIPEC and are 
detailed in  table 1 . For the present analysis, all patients with at least 
3 months of follow-up during the study period were identified.
 At the beginning of the surgical procedure, the entire abdomen 
was routinely explored to assess the extent of peritoneal carcino-
matosis. For objective assessment, the Peritoneal Cancer Index 
(PCI) according to Sugarbaker et al. was calculated  [13] . Cytore-
ductive surgery is generally deemed feasible if the PCI is 20 or 
smaller, which was one of our inclusion criteria, evaluated on pre-
operative CT scans. In nine patients, intraoperative exploration of 
the abdomen revealed a PCI larger than 20. The procedure was 
nonetheless continued in these patients because the surgeon 
judged it to be feasible taking into account the involvement of ab-
dominal regions according to Verwaal et al.  [4] .
 Interventions 
 For cytoreductive surgery, partial or total peritonectomy was 
performed as necessary and intraabdominal organs were resected 
depending on tumor dissemination. Hyperthermic chemoperfu-
sion was performed for 60 min with the inflow temperature set to 
41   °   C using the open ‘coliseum’ technique  [14] during this study. 
We used Mitomycin C and Cisplatin as chemotherapeutic agents, 
adding oxaliplatin in gastric cancer and docetaxel in ovarian cancer.
 Measurements 
 Quality of life was assessed preoperatively, 3 months, 9 months, 
and 18 months postoperatively using the EORTC QLQ-C30 ques-
tionnaire  [15] . Patients completed a paper-based version of the 
questionnaire, either alone or with the aid of an examiner. Patients 
were told that no right or wrong answers exist and that they should 
respond spontaneously. The QLQ-C30 contains 30 questions, 28 
of which allow 4 different answers, while the last two questions are 
answered using an analogue scale ranging from 1 to 7. At the time 
of analysis, these questions are grouped using a predefined for-
mula resulting in 1 scale for global health status, 5 functional scales, 
6 symptom scales, and 3 single items. Data were transformed into 
a scale from 0 to 100 as described in the Scoring Manual, 3rd edi-
tion  [16] . A high score on a functional scale or for general health 
status corresponds to good function or quality of life. In symptom 
scales and single items, a high score corresponds to more severe 
symptoms or problems in life.
 Statistical Analysis 
 Patients that completed at least 2 questionnaires (preoperative 
and 3 months postoperative) entered statistical analysis. In 5 pa-
tients, data were available until 18 months of follow-up. The SPSS 
software (version 17.0) was used for statistical analysis.
 Student’s  t test for paired samples was used to test for differ-
ences between preoperative and postoperative measurements. For 
general health status, we performed an analysis of variance for re-
peated measurements to confirm changes in quality of life over 
time. In a subgroup analysis, the  t test for unpaired samples was 
used to test for differences between sexes and between patients 
with high or low Peritoneal Cancer Index scores at the time of sur-
Table 1.  Inclusion and exclusion criteria for HIPEC
Inclusion criteria:
– Age >18 years and <70 years
– Limited peritoneal carcinomatosis: PCI <20 on preoperative 
CT scan
– Tumor entity suitable for HIPEC (colorectal carcinoma, 
 appendix carcinoma, carcinoma of the small intestine, gastric 
cancer, recurrent ovarian cancer, pseudomyxoma peritonei, 
primary peritoneal carcinomatosisa)
– Karnofsky index >70%
Exclusion criteria:
– Extraabdominal tumor
– Compromised liver kidney or bone marrow function
 PCI = Peritoneal cancer index. a Adenocarcinoma of the ovary 




















   
   
   
   
   
   
   
   
   
   
   


























gical exploration. We employed one-way analysis of variance to 
test for differences between tumor entities. A general linear model 
was used to confirm the results of subgroup analysis. A probabil-
ity value of p < 0.05 was deemed significant for all statistical tests.
 Results 
 Patient Characteristics 
 During the study period, 52 patients presented to our 
department for peritoneal carcinomatosis. Cytoreduc-
tion and HIPEC were performed in 40 of these patients 
after completion of preoperative workup. In 7 patients, 
3-months follow-up was not completed. Therefore, data 
from 33 patients entered statistical analysis. There were 
26 (65%) females and 14 males in this study. The young-
est patient was aged 35, the oldest 70 years, the mean age 
being 52 (53 years for men and 51 years for women, n.s.). 
Patients included in this study suffered from five different 
types of primary tumors ( table 2 ).
 Primary Outcome: Quality of Life 
 Complete questionnaires were available for analysis 
from 26 patients 3 months postoperatively. At 9 months, 
19 questionnaires were available and at 18 months, 7 
questionnaires.
 Global Health Status 
 Global health status was not influenced significantly 
by cytoreduction and HIPEC ( fig. 1 a). A nonsignificant 
reduction was observed 3 months postoperatively with 
scores returning to preoperative values within 9 months 
Table 2.  Quality-of-life measurements and subgroup analysis
 Quality of life
pre-op erative 3 months 9 months 18 months
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and staying on this level at 18 months. Analysis of vari-
ance for patients that completed 18 months of follow-up 
confirmed that a significant recovery occurred between 
3 months and 9 months postoperatively (p = 0.009), while 
postoperative scores were not lower than preoperative 
measurements.
 Functional Scales 
 Physical function (p < 0.001), role function (p < 0.001), 
and social function (p = 0.007) scores were reduced 
3 months postoperatively but recovered to preoperative 
scores at 9 months with equal scores at 18 months of fol-
low up ( fig. 1a ). Emotional and cognitive functions were 
not altered significantly following cytoreduction and 
HIPEC but showed a similar pattern.
 Symptom Scales and Single Items 
 Nausea and vomiting were not severe in our patients 
and there were no significant postoperative differences 
( fig. 1 b). Fatigue (p < 0.001), pain (p < 0.001), dyspnea 
(p  = 0.001), insomnia (p = 0.004), and diarrhea (p = 
0.015) were more frequent at 3 months compared to pre-
operative values but not 9 or 18 months. Appetite and 
the condition of constipation did not change postopera-
tively.
 Subgroup Analysis 
 Tumor Type. For general quality of life, no significant 
differences were observed between patients with different 
tumor types at 3 months follow-up. Patients with gastric 
cancer and pseudomyxoma peritonei had significantly 
lower preoperative scores (p = 0.019) than other tumor 
types and they showed no postoperative drop in quality 
of life. Recovery from 3 to 9 months was similar for all 
tumor types except for recurrent ovarian cancer patients 
who recovered more slowly ( table 2 ).
 Sex. Changes at 3 months follow-up were calculated 
 separately for male and female patients and tested for dif-
ferences between the sexes. Significant differences were 
found only for general health (p = 0.003) and emotional 
function (p = 0.008). For both items, these differences were 
due to a loss of function in female patients and simultane-
ous improvement in males. In addition, pre- and postop-
erative scores were compared between male and female pa-
tients. Women obtained higher preoperative scores for both 
general health and emotional function. At 3 months follow-
up, men improved significantly, reaching scores compara-
ble or even better than those of female patients ( table 2 ).
 PCI. No postoperative differences between patients 
with PCI >20 compared to patients with PCI  ≤ 20 were 
found ( table 2 ).
 Fig. 1. Quality of life assessment using the EORTC QLQ-C30 ques-
tionnaire. The graph shows the results for global health status and 
functional scales ( a ) as well as symptom scales and single items 
( b ). For some scales and symptoms, a significant deterioration was 
observed 3 months postoperatively. On all scales and symptoms, 
however, patients recovered to preoperative levels within 9 months 
postoperatively. At 18 months, scores obtained were equal or bet-
ter than at 9 months. Columns show mean values and standard 












































































   
   
   
   
   
   
   
   
   
   
   


























 General Linear Model. To further distinguish influenc-
ing factors, an analysis of covariance for general quality 
of life at 9 months (n = 16) with sex, tumor type, and PCI 
at surgical exploration as factors and preoperative as well 
as 3 months postoperative quality of life as covariates was 
performed. While long-term quality of life in this model 
was significantly correlated with quality of life at three 
months (p = 0.013), it did not depend on sex, tumor type, 
PCI, or preoperative quality of life.
 Postoperative Morbidity 
 Complications occurred in 14 patients (35%). Most 
frequent were ileus (4 patients), intestinal fistula/perfora-
tion, or anastomotic leakage, wound healing disorders 
and ostomy complications (3 patients each).
 Survival and Tumor Recurrence 
 Survival analysis included 32 patients. During the ob-
servation period, 7 patients (22%) died. Five patients 
(16%) died of tumor recurrence, one died of postopera-
tive pneumonia, and one patient died of unknown cause.
 At the end of the observation period, 15 patients (45%) 
had experienced tumor recurrence; 18 patients (55%) 
were disease-free.
 Weight Loss 
 For all patients, their preoperative body weight, lowest 
weight during the period of observation, and weight at 18 
months follow-up were documented. All patients lost 
weight following cytoreduction and HIPEC. Most pa-
tients gained weight until the termination of this study, 
some weighing more than before the operation ( table 3 ).
 Discussion 
 This study was designed to determine the impact of 
cytoreduction and HIPEC on health-related quality of life 
of patients with peritoneal carcinomatosis from different 
primary tumors. We used the EORTC QLQ-C30 ques-
tionnaire that has been extensively validated to assess the 
quality of life in tumor patients  [15] and is currently the 
preferred tool in Europe  [17] . Only the core question-
naire excluding tumor-specific sub-questionnaires was 
employed because peritoneal carcinomatosis was caused 
by different primary tumor entities in our patients. The 
score descriptively analyses symptoms, but does not allow 
for conclusions on the underlying causes. Fatigue, for ex-
ample, may be caused by (preexisting) mental depression 
or by the operation itself. Early postoperative quality of 
life was measured at 3 months to document symptoms 
caused by the surgical procedure. The latest evaluation at 
18 months was chosen to extend the observation time 
span beyond previous studies by other groups that ended 
at 12 months  [11, 18] . 
 Before the decision for HIPEC was made, all patients 
were staged according to the same standards using mod-
ern multi-slice CT scanners. Distant metastases were ex-
cluded and a Peritoneal Cancer Index (PCI) Score was 
calculated. Nonetheless, preoperative CT did not always 
correctly assess the extent of peritoneal carcinomatosis. 
The limited prognostic value of computed tomography 
for peritoneal carcinomatosis has been described previ-
ously  [19] . Intraoperative exploration revealed a PCI >20 
in nine of our patients, but the surgeon judged the proce-
dure to be technically feasible and HIPEC was success-
fully performed in all of these patients.
 Global health status was not impaired significantly 
3  months after surgery or at 9 months; some patients 
viewed their health to be even better than what it was be-
fore surgery. Scales and symptom scores that yielded a 
significant deterioration 3 months after surgery, that is, 
physical function, role function, social function, fatigue, 
pain, dyspnea, insomnia, and diarrhea, all returned to 
preoperative values within 9 months. At 9 months post-
operatively, 80% of patients were pain-free. For global 
health, role function, emotional function, fatigue, and ap-
petite, there even appeared to be a tendency toward im-
proved scores in comparison to preoperative values, but 
our study was not powered to verify these differences. Al-
though some survivorship bias must be assumed, these 
results justify the conclusion that cytoreductive surgery 
and HIPEC can be performed without negative long-term 
impact on the quality of life of surviving patients.
 Good or acceptable quality of life had been suggested 
by previous studies  [10, 11, 20], but their interpretation 
was limited by the fact that data had been collected retro-
spectively. Hill et al., in their prospective analysis of pa-
tients with peritoneal carcinomatosis of colonic origin, 
found a pattern of recovery similar to our patients with 
the exception of emotional function, which was signifi-
Table 3.  Weight development in male and female patients, kg (%)
Male Female Range
Preoperative weight 82.6 72.5 52–110
Lowest weight 64.2 (–22) 58.8 (–19) 42–92
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cantly improved in their study not including ovarian can-
cer patients  [18] .
 Interestingly, female patients in the present study 
reached lower postoperative scores for emotional function 
and general health status. Given the descriptive nature of 
the quality-of-life testing, no conclusions can be drawn as 
to any causal connection between the two. Nevertheless, 
the present study suggests that women find it harder to 
cope with cytoreductive surgery and HIPEC, while recur-
rence rates did not differ between the two sexes (p = 0.39, 
χ 2 test). The unfavorable development in female patients 
to some extent may have been due to the inclusion of pa-
tients with ovarian cancer who suffered from a second re-
currence with disease progression under chemotherapy: 
while patients with other primary tumors, at 9 months af-
ter the operation, reached quality-of-life scores 27 points 
higher than their preoperative values, ovarian cancer pa-
tients’ score deteriorated by 16 points (p = 0.045).
 Interestingly, our general linear model showed that 
while significant preoperative differences in quality of life 
between patients with various primary tumors may exist, 
postoperative quality of life did not depend on tumor en-
tity and recovery was comparable for patients with all 
types of primary tumor (except ovarian cancer). The 
analysis of covariance was limited by the relatively small 
number of cases in this study and high morbidity, which 
precluded an analysis of the quality of life at 18 months.
 Short-term quality of life, which reflects postoperative 
morbidity, had a more significant impact on long-term 
quality of life than any other factor analyzed. In this re-
spect, with postoperative quality of life being also inde-
pendent from the preoperative status, it can be concluded 
that the decision to offer HIPEC to a patient should be 
based only on the oncological prognosis and surgical con-
siderations but not on other factors such as sex or preop-
erative quality of life.
 A recent prospective study by Tsilimparis et al.  [21] 
showed a recovery of health-related quality of life similar 
to our data. This growing evidence from an increasing 
number of centers indicates that in this highly specialized 
field of oncological surgery, good results can be achieved 
not only in a few leading centers that may be operating in 
extremely favorable conditions but also in many different 
institutions and healthcare systems.
 For a more complete interpretation, these results 
should be compared to other aggressive surgical therapies. 
Schniewind et al., for example, found patients’ quality of 
life to be impaired for 3–6 months after pancreaticoduo-
denectomy for pancreatic cancer with recovery to preop-
erative levels within 12–24 months  [22] . This resembles 
the time course of recovery observed in the present study, 
suggesting that cytoreduction and HIPEC do not impair 
quality of life more than pancreaticoduodenectomy.
 It must be emphasized that most patients received ad-
juvant chemotherapy, which may have caused some of 
their symptoms, such as lack of appetite, nausea, and 
vomiting  [23] . Patients not receiving chemotherapy had 
better appetite and less nausea and vomiting (data not 
shown), which suggests that the contribution of cytore-
duction and HIPEC to these symptoms may have been 
overestimated in the past.
 Survival analysis was limited by the relatively short study 
length, which resulted in varying observation periods for 
our patients with a maximum of 35 months. With a 22% 
mortality rate and only 19 questionnaires from 28 surviv-
ing patients available over a period of 9 months, selection 
bias favoring healthier patients must be assumed and con-
clusions from our study should be drawn cautiously.
 Overall morbidity in the present study was 35%, which 
compares well to data published by other groups  [6–9] . It 
must be mentioned, however, that in these earlier studies, 
the HIPEC procedure and its indications were still being 
evaluated, resulting in increased morbidity and toxicity.
 Almost all patients lost weight in the early postoperative 
period but regained at least some of it until the end of the 
observation period. The loss of weight observed in the pres-
ent study (females: 15%, males: 17%) was somewhat more 
pronounced when compared, for instance, to Whipple’s 
operation  [24] , colectomy, or partial resection of the small 
intestine but did not significantly impair quality of life.
 Conclusion 
 In most patients, quality of life recovered to preoperative 
levels or higher within 9 months after cytoreduction and 
HIPEC with very good long-term results at 18  months. 
Postoperative quality of life did not depend on sex, primary 
tumor site, or preoperative quality of life. Results are com-
parable to other types of large abdominal surgery, such as 
Whipple’s operation. Pain was relatively mild and vegeta-
tive disorders could to a large extent be attributed to chemo-
therapy. Selected patients that are likely to benefit oncolog-
ically from cytoreduction and HIPEC should not be denied 
this option for fear of reduced postoperative quality of life.
 Disclosure Statement 
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